Good morning. Elizabeth Cooney here, filling in for the vacationing Ed Silverman. As the working week draws to a close, it is my treasured signal to hand the Pharmalittle keys back to Ed. He’ll see you Monday.
The FDA wants to know whether the long lists of side effects in drug ads are making consumers’ eyes glaze over, STAT informs us. But the study, and related work at the FDA, have irked the drug industry and spurred critics of direct-to-consumer drug advertisements to argue the agency should be doing more. Meanwhile, the Senate voted to give the Department of Health and Human Services at least $1 million to issue regulations requiring prescription drug ads to include the price of the medicine, STAT also tells us.
About the Author Reprints
